50882-29-6

Basic information

• Product Name: phenyl N-(4-bromophenyl)carbamate
• Synonyms: phenyl N-(4-bromophenyl)carbamate;phenyl(4-bromophenyl)carbamate;EOS-60613;Phenyl N-(4-Bromophenyl)Carbamate(WXC04741)
• CAS NO: 50882-29-6
• Molecular Formula: C₁₃H₁₀BrNO₂
• Molecular Weight: 292.128
• Mol File: 50882-29-6.mol
• Article Data: 15

Chemical Properties

• Melting Point: 154 °C
• Boiling Point: 359.6±34.0 °C(Predicted)
• Appearance: /
• Density: 1.532±0.06 g/cm3(Predicted)
• PKA: 12.15±0.70(Predicted)
• CAS DataBase Reference: phenyl N-(4-bromophenyl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: phenyl N-(4-bromophenyl)carbamate(50882-29-6)
• EPA Substance Registry System: phenyl N-(4-bromophenyl)carbamate(50882-29-6)

Safety Data

• Hazardous Substances Data: 50882-29-6(Hazardous Substances Data)

Upstream product

• 1885-14-9 phenyl chloroformate 
• 106-40-1 4-bromo-aniline 
• 14917-59-0 p-bromobenzoyl azide 
• 108-95-2 phenol 

Downstream Products

• 1315592-05-2 4-((4-bromophenyl)aminoformyl)piperazine-1-carboxylic acid tert-butyl ester 
• 158525-82-7 4-methyl-N-(4-bromophenyl)-benzamide 
• 1219729-13-1 3-(4-bromophenyl)-1-(2-hydroxyethyl)-1-(3-methoxybenzyl)urea 
• 1219722-68-5 1-(2-hydroxyethyl)-1-(3-methoxybenzyl)-3-[4-(1H-pyrazol-4-yl)phenyl]urea 

Relevant articles and documents

ROR [gamma]t inhibitor and application in medicine

The invention belongs to the technical field of medicines, and particularly relates to an ROR [gamma]t inhibitor and application in medicines. The invention also relates to a method for preparing the compound and a pharmaceutical composition containing the compound, and application of the compound and the pharmaceutical composition in treatment or prevention of ROR [gamma]t-mediated cancers, inflammations or autoimmune diseases of mammals, especially human beings.

Design, synthesis, and biological activity of novel semicarbazones as potent Ryanodine receptor1 inhibitors of Alzheimer's disease

Ryanodine receptors (RyRs) are important ligand-gated Ca2+ channels; their excessive activation leads to Ca2+ leakage in the sarcoplasmic reticulum that may cause neurological diseases. In this study, three series of novel potent RyR1 inhibitors based on dantrolene and bearing semicarbazone and imidazolyl moieties were designed and synthesized, and their biological activity was evaluated. Using a single-cell calcium imaging method, the calcium overload inhibitory activities of 26 target compounds were tested in the R614C cell line, using dantrolene as a positive control. The preliminary investigation showed that compound 12a suppressed Ca2+ release as evidenced by store overload-induced Ca2+release (SOICR) (31.5 ± 0.1%, 77.2 ± 0.1%, 93.7 ± 0.2%) at 0.1 μM, 3 μM and 10 μM, respectively. Docking simulation results showed that compound 12a could bind at the active site of the RyR1 protein. The Morris water-maze test showed that compound 12a significantly improved the cognitive behavior of AD-model mice. Further studies on the structural optimization of this series of derivatives are currently underway in our laboratory.

NOVEL ARYL OR HETEROARYL TRIAZOLONE DERIVATIVES OR SALTS THEREOF, OR PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The aryl or heteroaryl triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).